)
)
)
D2M Biotherapeutics
D2M is transforming immunology and oncology drug discovery and development empowered by human genetic insights. D2M is progressing several assets to IND on genetics validated targets. The pipeline includes:
DM919: an antibody targeting a key tumor immune escape mechanism of natural killer cells.
DM618: a FIC candidate targeting a genetic validated Th1 cell target for a broad set of I&I diseases.
D2M016: a next generation T-reg targeted IL-2 mutein for immune diseases.
D2M018: a cis-interacted anti-PD-1 and IL-2 mutein for oncology.
Address
NatickMassachusetts
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)